2157 — Lepu Biopharma Co Income Statement
0.000.00%
Last trade - 00:00- HK$8.26bn
- HK$8.35bn
- CNY934.87m
Annual income statement for Lepu Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 15.6 | 225 | 368 | 935 |
| Cost of Revenue | |||||
| Gross Profit | — | 13.6 | 197 | 293 | 845 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,010 | 720 | 221 | 759 | 650 |
| Operating Profit | -1,010 | -704 | 4.8 | -391 | 285 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,029 | -699 | -30.3 | -424 | 261 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,029 | -699 | -30.3 | -424 | 259 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,011 | -689 | -22.1 | -411 | 261 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,011 | -689 | -22.1 | -411 | 261 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.587 | -0.399 | -0.013 | -0.243 | 0.042 |